Business Context and Reporting Period
Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2025 (Event Date)
Reporting Period: Specific event date; not a periodic financial report.
Key Financial Metrics and Capital Structure
- New Financing: Entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital Corporation.
- Initial Funding: $350 million Initial Term Loan funded on July 17, 2025.
- Available Commitments: Up to $150 million in Delayed Draw Term Loans (available until December 31, 2027) and up to $250 million in uncommitted Incremental Term Loans.
- Interest Rates: Base Rate + 3.75% (Base Rate floor 2.00%) or Term SOFR + 4.75% (SOFR floor 1.00%).
- Maturity Date: July 17, 2030.
- Liquidity Covenant: Must maintain a minimum unrestricted cash balance of $100 million.
- Collateral: First priority security interest in substantially all assets of the Company and Guarantors.
Material Changes Versus Prior Period
- Debt Refinancing: Used proceeds from the new Initial Term Loan to fully repay $121.6 million in outstanding obligations under the previous Loan and Security Agreement with Hercules Capital, Inc.
- Debt Composition: Repayment included $115.0 million of principal plus accrued interest and exit fees.
- Agreement Termination: The Existing Loan Agreement dated May 9, 2022, was terminated, releasing all associated security interests and guarantees.
Outlook, Risks, and Management Commentary
- Prepayment Terms: The Company may prepay loans at any time. Mandatory prepayments may be required upon certain events. Prepayment fees may apply, capped at 3.00% of the prepaid amount plus a make-whole amount.
- Covenants: The agreement includes customary affirmative and negative covenants.
- Events of Default: Includes a change of control provision. Upon default, lenders may accelerate obligations.
- Disclosure: A press release regarding this financing was issued on July 22, 2025 (Exhibit 99.1).
Investor Verification Checklist
- Verify the full text of the Financing Agreement and Security Agreement when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
- Confirm the specific terms of the "customary prepayment events" that trigger mandatory prepayments.
- Monitor the Company's ability to maintain the $100 million minimum unrestricted cash balance covenant.
- Review the press release (Exhibit 99.1) for additional management commentary on the strategic use of proceeds.